XGEVA (denosumab) - Important Safety Information from Amgen as approved by the Irish Medicines Board
04 September 2012
Important Safety Information communication from Amgen on the risk of severe symptomatic hypocalcaemia associated with the use of denosumab and the risk of late onset of hypocalcaemia.
Important Safety Information - XGEVA (denosumab)